Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.
Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, Keech J Jr, Chmielecki J. Parachoniak CA, et al. Among authors: morosini d. Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5):a000778. doi: 10.1101/mcs.a000778. Print 2017 Sep. Cold Spring Harb Mol Case Stud. 2017. PMID: 28550065 Free PMC article.
Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS, Wang K, Rand JV, Gay L, Presta MJ, Sheehan CE, Ali SM, Elvin JA, Labrecque E, Hiemstra C, Buell J, Otto GA, Yelensky R, Lipson D, Morosini D, Chmielecki J, Miller VA, Stephens PJ. Ross JS, et al. Among authors: morosini d. J Clin Pathol. 2014 Nov;67(11):968-73. doi: 10.1136/jclinpath-2014-202514. Epub 2014 Jul 30. J Clin Pathol. 2014. PMID: 25078331 Free PMC article.
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Frampton GM, et al. Among authors: morosini d. Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13. Cancer Discov. 2015. PMID: 25971938
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M. Ross JS, et al. Among authors: morosini d. Breast Cancer Res Treat. 2015 Nov;154(1):155-62. doi: 10.1007/s10549-015-3592-z. Epub 2015 Oct 12. Breast Cancer Res Treat. 2015. PMID: 26458824
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George TJ Jr, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B. Williams CB, et al. Among authors: morosini d. Onco Targets Ther. 2015 Dec 1;8:3561-4. doi: 10.2147/OTT.S90766. eCollection 2015. Onco Targets Ther. 2015. PMID: 26664139 Free PMC article.
30 results